454 related articles for article (PubMed ID: 17470758)
1. Postmarketing modifications in the safety labeling of the new antiepileptics.
Buck ML; Gurka MJ; Goodkin HP
Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
[No Abstract] [Full Text] [Related]
2. A quantitative analysis of adverse events and "overwarning" in drug labeling.
Duke J; Friedlin J; Ryan P
Arch Intern Med; 2011 May; 171(10):944-6. PubMed ID: 21606101
[No Abstract] [Full Text] [Related]
3. How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications.
Ehrenpreis ED; Ciociola AA; Kulkarni PM;
Am J Gastroenterol; 2012 Apr; 107(4):501-4. PubMed ID: 22475958
[No Abstract] [Full Text] [Related]
4. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
O'Reilly JT
Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
[No Abstract] [Full Text] [Related]
5. Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.
Jacobson JD; Feigal D
Food Drug Law J; 2007; 62(3):529-46. PubMed ID: 17915395
[No Abstract] [Full Text] [Related]
6. Improving drug safety monitoring.
Karande S; Gogtay NJ; Kshirsagar NA
Indian Pediatr; 2003 Dec; 40(12):1167-75. PubMed ID: 14722367
[TBL] [Abstract][Full Text] [Related]
7. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
8. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
Noah BA; Brushwood DB
J Health Law; 2000; 33(3):383-454. PubMed ID: 11184355
[TBL] [Abstract][Full Text] [Related]
9. Canadian and US drug approval times and safety considerations.
Rawson NS; Kaitin KI
Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
[TBL] [Abstract][Full Text] [Related]
10. A drug is not a drug is not a drug: a commentary.
Struijker Boudier HA
Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):437-8. PubMed ID: 12426926
[No Abstract] [Full Text] [Related]
11. Reform of drug regulation--beyond an independent drug-safety board.
Ray WA; Stein CM
N Engl J Med; 2006 Jan; 354(2):194-201. PubMed ID: 16407517
[No Abstract] [Full Text] [Related]
12. "Safer, but not safe enough".
Crombie HD
Conn Med; 2006; 70(10):645. PubMed ID: 17190395
[No Abstract] [Full Text] [Related]
13. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
Issa AM
Pharmacogenomics; 2003 Sep; 4(5):647-55. PubMed ID: 12943471
[TBL] [Abstract][Full Text] [Related]
14. Drug withdrawals from the Canadian market for safety reasons, 1963-2004.
Lexchin J
CMAJ; 2005 Mar; 172(6):765-7. PubMed ID: 15767610
[No Abstract] [Full Text] [Related]
15. Letter to the ISPE commentary editor.
Rawson NS
Pharmacoepidemiol Drug Saf; 2003; 12(1):71-2. PubMed ID: 12616851
[No Abstract] [Full Text] [Related]
16. The drug safety system conundrum.
Tiedt TN
Food Drug Law J; 2007; 62(3):547-558. PubMed ID: 17915396
[No Abstract] [Full Text] [Related]
17. Evaluating drug effects in the post-Vioxx world: there must be a better way.
Avorn J
Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
[No Abstract] [Full Text] [Related]
18. Monitoring and assessing vaccine safety: a European perspective.
Lopalco PL; Johansen K; Ciancio B; De Carvalho Gomes H; Kramarz P; Giesecke J
Expert Rev Vaccines; 2010 Apr; 9(4):371-80. PubMed ID: 20370548
[TBL] [Abstract][Full Text] [Related]
19. When is a medical product too risky? An interview with FDA's top drug official. Interview by Tamar Nordenberg.
Woodcock J
FDA Consum; 1999; 33(5):8-11, 13. PubMed ID: 10522164
[No Abstract] [Full Text] [Related]
20. Safety in numbers--monitoring risk in approved drugs.
Okie S
N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
[No Abstract] [Full Text] [Related]
[Next] [New Search]